Six weeks of intranasal oxytocin in 106 autistic adults increased the metabolite N,N-dimethylglycine (d=0.74), which correlated with both the early improvement (2 weeks) and subsequent decline (2-4 weeks) of oxytocin's social benefits — implicating NMDA receptor plasticity.
d = 1.13 in respondersN,N-dimethylglycine increase showed a large effect size in oxytocin responders, and its levels tracked both the initial clinical improvement and subsequent tolerance
What the researchers found
Oxytocin increased N,N-dimethylglycine (FDR p=0.043, d=0.74; N=83). In high-responder subgroup: FDR p=0.004, d=1.13, N=60. DMG increase correlated with clinical improvement at 2 weeks (r=-0.485, p=0.006) and deterioration at 2-4 weeks (r=0.415, p=0.032).
Why it matters
This explains the biggest puzzle in oxytocin-ASD research: why benefits don't last. The NMDA receptor/plasticity mechanism suggests that intermittent dosing or combination approaches could maintain oxytocin's benefits without tolerance.
The numbers in context
N=106; DMG d=0.74 (p=0.043); subgroup d=1.13 (p=0.004); improvement r=-0.485; deterioration r=0.415; 48 IU/day; 6 weeks
How the study worked
Multi-center, parallel-group, double-blind, placebo-controlled RCT. 106 adult males with ASD. Intranasal oxytocin 48 IU/day or placebo for 6 weeks. Plasma metabolomics (35 metabolites). Facial expression analysis for clinical outcomes. UMIN000015264.
Who was studied
Adult males with autism spectrum disorder
What this study cannot tell us
Blood metabolites may not reflect brain changes. Only adult males studied. Facial expression analysis as clinical outcome is novel but not a standard ASD measure. Subgroup analyses reduce statistical power. Correlation does not prove causation.
How to read the evidence
Moderate-to-high evidence: multi-center double-blind RCT with 106 participants, metabolomics, and quantitative clinical outcomes. Mechanistic insights are correlational.
When this study was published
Published 2021. Oxytocin dosing optimization for ASD continues to be investigated based on time-course insights like these.
The bigger picture
Understanding why drug effects wane over time is crucial for many neuropeptide therapies. The DMG-NMDA plasticity link suggests that oxytocin triggers a learning-like process in social brain circuits — initially beneficial but self-limiting, similar to synaptic plasticity mechanisms.
Questions still open
- Would intermittent oxytocin dosing (e.g., pulsed administration) maintain efficacy by preventing tolerance?
- Could combining oxytocin with NMDA receptor modulators (like D-cycloserine) extend its benefits?
- Does the same DMG-mediated time course occur in children with ASD?
Common questions
Why does oxytocin stop working for autism after a few weeks?
What does this mean for oxytocin treatment dosing?
Read the original research
Oxytocin-induced increase in N,N-dimethylglycine and time course of changes in oxytocin efficacy for autism social core symptoms.
Molecular autism, 12(1), 15
Citation
Kato, Yasuhiko; Kuwabara, Hitoshi; Okada, Takashi; Munesue, Toshio; Benner, Seico; Kuroda, Miho; Kojima, Masaki; Yassin, Walid; Eriguchi, Yosuke; Kameno, Yosuke; Murayama, Chihiro; Nishimura, Tomoko; Tsuchiya, Kenji; Kasai, Kiyoto; Ozaki, Norio; Kosaka, Hirotaka; Yamasue, Hidenori. (2021). Oxytocin-induced increase in N,N-dimethylglycine and time course of changes in oxytocin efficacy for autism social core symptoms.. Molecular autism, 12(1), 15. https://doi.org/10.1186/s13229-021-00423-z